This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
AstraZeneca (AZN.L) – U.S. government was closing a probe into a major clinical trial used to win marketing approval for its new heart drug Brilinta and no further action was planned. Is a potential $3.5bn-a-year seller but which has so far registered only modest sales. The promise of this drug was flagged up when AstraZeneca rejected Pfizer’s takeover bid. Closing price 4201.00p. (Reuters)
Imperial Tobacco (IMT.L) – Expected to report modest adjusted earnings growth in the full year after volumes from its top growth brands rose by 3% in the first nine months. Reiterated its target of a 10% hike to its dividend. Cost cutting programme remained on track. Closing price 2526.00p. (Reuters)
Persimmon (PSN.L) – H1 pretax profit rises 57%. Legal completions up 28% to 6,408 new homes sold, average selling price up 4.3% to £186,970. Remains confident of its continued successful development. Closing price 1335.00p. (Reuters)
John Wood Group (WG.L) – H1 total revenue of $3,801.2m up 10% and total EBITA in line with H1 2013 at $243.9m. Interim dividend of 8.9 cents (2013: 7.1 cents) up 25%. H1 revenue from continuing operations on an equity accounting basis up 16% at $3,224.4m. Closing Price 751.50p (Reuters)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| Carillion | CLLN.L | 1.29% | 2.13% | -0.51% |
| Balfour Beatty | BALF.L | 3.38% | 3.71% | 0.33% |
| Bovis Homes | BVS.L | 4.49% | 7.11% | 0.62% |
| Taylor Wimpey | TW.L | 0.35% | 0.61% | -1.67% |
| Barratt Developments | BDEV.L | 1.22% | 1.47% | -1.67% |
| Persimmon | PSN.L | 1.75% | 1.91% | -1.60% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research